60 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
on the business, results of operations and financial condition of the Company.
Litigation
The Company may become party to litigation from time to time … in the ordinary course of business which could adversely affect its business. Should any litigation in which the Company becomes involved be determined
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
significantly;
we may be subject to litigation or product liability claims; and
our reputation may suffer.
Any of these events could prevent us or our … scrutiny;
significant litigation costs;
substantial monetary awards to or costly settlement with patients or other claimants;
product recalls
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:17pm
that this representation is made.
(p) Litigation. Except as set forth in the SEC Reports, there is no material action, suit, inquiry, notice of violation, proceeding
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
a material adverse effect on the business, results of operations and financial condition of the Company.
Litigation
The Company may become party … to litigation from time to time in the ordinary course of business which could adversely affect its business. Should any litigation in which the Company
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
on the business, results of operations and financial condition of the Company.
Litigation
The Company may become party to litigation from time to time … in the ordinary course of business which could adversely affect its business. Should any litigation in which the Company becomes involved be determined
424B3
o0r94
13 Jun 24
Prospectus supplement
4:11pm
424B3
d0ka27
13 Jun 24
Prospectus supplement
4:10pm
424B3
r9d1f8sb3m 5uppoz
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.2
tqjau3m34z59phe1ul
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-10.1
dkk yen9y5
30 Nov 23
XORTX Announces US ATM Offering
4:04pm
424B5
2f0fjhdwcuhh5h1em
29 Nov 23
Prospectus supplement for primary offering
9:57pm
6-K
EX-99.2
ak1mxj
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
424B3
53fo4t58brfcist
25 Aug 23
Prospectus supplement
6:00am
424B3
uchz ky5kf
25 Aug 23
Prospectus supplement
6:00am
6-K
EX-99.2
k0m8gx
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
POS AM
sxu zancgr794fa4
4 Aug 23
Prospectus update (post-effective amendment)
4:08pm
POS AM
gpro d3cihy7g6
4 Aug 23
Prospectus update (post-effective amendment)
4:05pm
6-K
EX-99.2
bdj3vx7
30 May 23
Notice of Annual & Special Meeting of Shareholders
7:00am